6,355 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,355 shares of the company’s stock, valued at approximately $290,000.

Other institutional investors have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its position in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at about $128,000. Bayesian Capital Management LP bought a new stake in shares of Keros Therapeutics in the 1st quarter valued at about $267,000. Quest Partners LLC grew its position in shares of Keros Therapeutics by 23,945.0% in the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after buying an additional 4,789 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at about $228,000. Institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

KROS has been the topic of several research analyst reports. Guggenheim initiated coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Truist Financial restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Oppenheimer initiated coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Finally, Bank of America cut their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics has a consensus rating of “Buy” and a consensus price target of $90.63.

Insider Transactions at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 22.90% of the company’s stock.

Keros Therapeutics Stock Performance

KROS stock opened at $56.45 on Monday. The stock’s 50 day simple moving average is $50.14 and its 200 day simple moving average is $52.54. Keros Therapeutics, Inc. has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The company has a market cap of $2.04 billion, a P/E ratio of -10.96 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same period in the previous year, the business posted ($1.27) earnings per share. Equities analysts predict that Keros Therapeutics, Inc. will post -4.88 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.